Celyad Presents Update on CYAD01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

Standalone CYAD-01 without preconditioning leads to disease stabilization in three out of 11 metastatic colorectal cancer (mCRC) patients in THINK Phase 1 trial Initial data from first dose cohort...

More From BioPortfolio on "Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting"